Laura Soucek (Peptomyc), Montserrat Vendrell (Alta Life Science) and Marie-Eve Beaulieu (Peptomyc).


We are very pleased to announce the closure of a Series A financing of 4.2 million euros, led by Alta Life Sciences Spain I FCR, and we welcome the opportunity to work with an amazing team of experts in the development and commercialization of products in all areas of life sciences and across both sides of the Atlantic. This investment round also includes Healthequity and Business Angels that had already participated in the seed round of 2016 and that renewed their support and trust in us.

This investment provides the capital necessary to significantly advance the industrial CMC manufacturing of our peptides and their validation in safety and efficacy non-clinical regulatory studies.

About Alta Life Sciences:

Alta Life Sciences is a new leading venture capital investment firm headquartered in Barcelona, that acts as investment advisor to the fund ALSS I FCR. The fund invests in companies at all stages of development: from seed financing through commercial growth, and in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

Altamar Private Equity SGIIC, a leading independent firm in the management of international Private Equity and other alternative assets, is ALSS I FCR’s management company.